<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158453</url>
  </required_header>
  <id_info>
    <org_study_id>AUT011201</org_study_id>
    <nct_id>NCT04158453</nct_id>
  </id_info>
  <brief_title>Safety, Blood Levels and Effects of AUT00201</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00201 in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autifony Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Autifony Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study medicine is a potential future treatment for schizophrenia, an illness that affects&#xD;
      the way that people think, feel or behave. It is not clear what causes schizophrenia, but&#xD;
      it's been linked to chemical imbalance in the brain. It is hoped that the study medicine will&#xD;
      activate specific sites in the brain to help correct that imbalance. Current treatments for&#xD;
      schizophrenia don't work very well and can cause unpleasant side effects. It is hoped that&#xD;
      the study medicine will work better, and have fewer side effects than existing medicines.&#xD;
&#xD;
      In this 2 part study (Part A: up to 40 healthy male subjects and up to 8 healthy female&#xD;
      subjects, Part B: up to 32 healthy male subjects) the primary aim is to assess how safe the&#xD;
      study medicine is in healthy men and women.&#xD;
&#xD;
      This study will be in 2 parts, as follows:&#xD;
&#xD;
      Part A will assess single doses of AUT00201 and Part B will assess multiple doses. Part A&#xD;
      will be divided into 3 sub-parts: Part A1 will assess single ascending doses in healthy men,&#xD;
      Part A2 will assess single ascending doses in healthy women, and Part A3 will assess the&#xD;
      effect of food on the PK of AUT00201 in healthy men.&#xD;
&#xD;
      A pharmaceutical company, Autifony Therapeutics Limited, is funding the study. The study will&#xD;
      take place at 1 centre in London.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Actual">December 24, 2020</completion_date>
  <primary_completion_date type="Actual">December 14, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects with treatment-related adverse events</measure>
    <time_frame>Study Duration (2 weeks post last dose)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>AUT00201</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AUT00201</intervention_name>
    <description>Oral dose of AUT00201</description>
    <arm_group_label>AUT00201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral dose of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normotensive male (all groups except Part A2) or female (Part A2 only) volunteers&#xD;
&#xD;
          -  Must have body mass index (BMI) of 18.0-31.0 kg/m2&#xD;
&#xD;
          -  Must be healthy based on clinical history, physical examination, ECG, vital signs, and&#xD;
             laboratory tests of blood and urine&#xD;
&#xD;
          -  Must be able to give fully informed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        History or presence of&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Severe head injury, or any other chronic neurological condition or any psychiatric&#xD;
             disorder&#xD;
&#xD;
          -  Abnormal screening EEG (Part A1 and Part B only)&#xD;
&#xD;
          -  Positive tests for hepatitis B &amp; C, HIV&#xD;
&#xD;
          -  Severe adverse reaction to any drug&#xD;
&#xD;
          -  Sensitivity to trial medication&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Use of over-the-counter medication within previous 7 days (with the exception of&#xD;
             Paracetamol [acetaminophen])&#xD;
&#xD;
          -  Prescribed medication during previous 28 days&#xD;
&#xD;
          -  Participation in other clinical trials of unlicensed medicines&#xD;
&#xD;
          -  Loss of more than 400 mL blood, within the previous 3 months&#xD;
&#xD;
          -  Vital signs or QTcF interval outside the acceptable range&#xD;
&#xD;
          -  Clinically relevant abnormal findings at the screening assessment&#xD;
&#xD;
          -  Acute or chronic illness&#xD;
&#xD;
          -  Clinically relevant abnormal medical history or concurrent medical condition&#xD;
&#xD;
          -  Positive result for suicidal ideation or behaviour using the Colombia suicide severity&#xD;
             rating scale (C-SSRS)&#xD;
&#xD;
          -  Possibility that volunteer will not cooperate&#xD;
&#xD;
          -  Pre-menopausal females who are pregnant or lactating, or who are sexually active and&#xD;
             not using a reliable method of contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Schizophrenia</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

